Hypersensitivity reactions to marijuana

Tessmer, Ayla; Berlin, Noam; Sussman, Gordon; Leader, Nathan; Chung, Eddie Chu; Beezhold, Donald H.

doi:10.1016/j.anai.2012.01.008

Cited by 49 publications

(39 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Periorbital angioedema may occasionally be triggered by cannabis allergens that became airborne (Tessmer et al 2012). Finally, anaphylaxis can result from ingestion of hempseed (Stadtmauer et al 2003) and from drinking marihuana tea (Tessmer et al 2012).…”

Section: Clinical Manifestationsmentioning

confidence: 99%

“…Presently, sensitization and allergy to cannabis are almost exclusively studied or documented by prick-prick skin testing. Prick-prick skin tests use a broad variety of raw materials such as macerated C. sativa leaves, buds and flowers de Larramendi et al 2008;Ebo et al 2013;Gamboa et al 2007;Larramendi et al 2013;Metz-Favre et al 2011;Nayak et al 2013;Stadtmauer et al 2003;Tessmer et al 2012). Needless to say, this approach is virtually impossible to standardize, mainly because of unpredictable variations in composition and potential contaminations with other allergens of the raw material.…”

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Cannabis Allergy: What do We Know Anno 2015

Decuyper

Ryckebosch

Gasse

et al. 2015

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

For about a decade, IgE-mediated cannabis (marihuana) allergy seems to be on the rise. Both active and passive exposure to cannabis allergens may lead to a cannabis sensitization and/or allergy. The clinical manifestations of a cannabis allergy can vary from mild to lifethreatening reactions, often depending on the route of exposure. In addition, sensitization to cannabis allergens can trigger various secondary cross-allergies, mostly for plant-derived food. This clinical entity, which we have designated as the ''cannabis-fruit/vegetable syndrome'' might also imply cross-reactivity with tobacco, latex and plant-food derived alcoholic beverages. These secondary cross-allergies are mainly described in Europe and appear to result from cross-reactivity between non-specific lipid transfer proteins or thaumatin-like proteins present in Cannabis sativa and their homologues that are ubiquitously distributed throughout plant kingdom. At present, diagnosis of cannabis-related allergies rests upon a thorough history completed with skin testing using native extracts from buds and leaves. However, quantification of specific IgE antibodies and basophil activation tests can also be helpful to establish correct diagnosis. In the absence of a cure, treatment comprises absolute avoidance measures including a stop of any further cannabis (ab)use.

show abstract

Section: Clinical Manifestationsmentioning

confidence: 99%

Section: Diagnosismentioning

confidence: 99%

Cannabis Allergy: What do We Know Anno 2015

Decuyper

Ryckebosch

Gasse

et al. 2015

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

show abstract

“…Although no testing was performed to assess the microbial burden of these samples, it is noted that most of these patients were SPT negative to Aspergillus. 3 …”

Section: Ige Reactivity To Various Parts Of C Sativa Plantmentioning

confidence: 99%

“…3 The most common symptoms following exposure to marijuana included rhinitis and conjunctivitis, periorbital angioedema, wheezing and contact urticaria. Most SPT positive patients had primary exposure to C. sativa either through smoking and direct contact to the plant.…”

Section: Patient Populationmentioning

confidence: 99%

“…1 As a result of the increasing social and medical usage, reports of allergic sensitization to marijuana are increasing in the peer reviewed literature. [2][3][4][5][6][7][8][9][10] Cases have been reported where hypersensitivity and even anaphylactic responses have been associated with marijuana use and clinical symptoms include sore throat, nasal congestion, rhinitis, pharyngitis, wheezing, dyspnea, angioedema and lacrimation. 2-4, 11, 12 In chronic and high dose users more severe manifestations of bronchitis and asthma with reduced vital capacity have been reported.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of Cannabis Sativa Allergens

Nayak

Green

Sussman

et al. 2013

Journal of Allergy and Clinical Immunology

Self Cite

View full text Add to dashboard Cite

Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients

Bryant

Daniels

Cognetti

et al. 2018

Laryngoscope Investig Oto

View full text Add to dashboard Cite

Objectives1) review benefits and risks of cannabis use, with emphasis on otolaryngic disease processes; 2) define and review the endocannabinoid signaling system (ESS); and 3) review state and federal regulations for the use and research of cannabis and ESS modulators.MethodsThis manuscript is a review of the current literature relevant to the stated objectives.ResultsCannabis (marijuana) use is increasing. It is the most widely used illicit substance in the world. There is increasing interest in its therapeutic potential due to changing perceptions, new research, and legislation changes controlling its use. The legal classification of cannabis is complicated due to varied and conflicting state and federal laws. There are currently two synthetic cannabinoid drugs that are FDA approved. Current indications for use include chemotherapy‐related nausea and vomiting, cachexia, and appetite loss. Research has demonstrated potential benefit for use in many other pathologies including pain, inflammatory states, and malignancy. Data exists demonstrating potential antineoplastic benefit in oral, thyroid, and skin cancers.ConclusionsESS modulators may play both a causal and therapeutic role in several disorders seen in otolaryngology patients. The use of cannabis and cannabinoids is not without risk. There is a need for further research to better understand both the adverse and therapeutic effects of cannabis use. With increasing rates of consumption, elevated public awareness, and rapidly changing legislation, it is helpful for the otolaryngologist to be aware of both the adverse manifestations of use and the potential therapeutic benefits when talking with patients.

show abstract

Hypersensitivity reactions to marijuana

Cited by 49 publications

References 7 publications

Cannabis Allergy: What do We Know Anno 2015

Cannabis Allergy: What do We Know Anno 2015

Characterization of Cannabis Sativa Allergens

Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients

Contact Info

Product

Resources

About